Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males
NCT04481789Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity, Maximum Plasma Concentration and 3 more. Started Oct 2018; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04481789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481789.